The notices it replaced
1 notice since 2023, oldest first, each with its awards since FY2014.
- Posted 2023RFA-TR-23-0164 awards
- Posted 2024RFA-TR-24-023This notice, closed · 6 awards
Replaced by RFA-TR-25-002.
Who won it before
Competing awards, new and renewals, since FY2014, under this notice and the notices it replaced.
- Past awards
- 10
- 10 new
- Median first-year cost
- $423,384
- $3,798,962 in all
- Institutions
- 10
- 10 contact PIs
Awards by fiscal year
0
0
0
0
0
0
0
0
0
0
4
6
0
14151617181920212223242526
Fiscal years 2014 to 2026.
Most frequent institutions
- CHILDREN'S HOSP OF PHILADELPHIA1
- CLEMSON UNIVERSITY1
- DUKE UNIVERSITY1
- MYOGENE BIO, LLC1
- NORTHWESTERN UNIVERSITY1
and 5 other institutions
Most frequent study sections
- Special Emphasis Panel (ZTR1 RD-1 (01))10
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| FY2025 | RepSox and its analog for prophylactic intervention in RUNX1 haploinsufficiency FPDMM1R21TR005192-01A1 | Poncz, Mortimer | CHILDREN'S HOSP OF PHILADELPHIA, PA | First-year cost $489,500 | Study section ZTR1 |
| FY2025 | Development of anti-LTBP4 as a biologic to treat Limb Girdle Muscular Dystrophy 2C1R21TR005472-01 | Demonbreun, Alexis R.McNally, Elizabeth M | NORTHWESTERN UNIVERSITY, IL | First-year cost $440,000 | Study section ZTR1 |
| FY2025 | Src Homology and Collagen (Shc) inhibition for the treatment of transplant-related pulmonary fibrosis.1R21TR005507-01 | Hsu, Joe L | STANFORD UNIVERSITY, CA | First-year cost $427,392 | Study section ZTR1 |
| FY2025 | Optimization and Preclinical Validation of QTE Therapy for Friedreich's Ataxia1R21TR005475-01 | Chandran, Vijayendran | UNIVERSITY OF FLORIDA, FL | First-year cost $419,375 | Study section ZTR1 |
| FY2025 | Optimization of delivery of HEX for treatment of primary amebic encephalitis1R21TR005502-01 | Chouinard, Christopher DonaldMorris, James Culvin | CLEMSON UNIVERSITY, SC | First-year cost $419,375 | Study section ZTR1 |
| FY2025 | Prevention of heterotopic ossification with localized delivery of arsenic trioxide loaded nanoparticles as a novel treatment for fibrodysplasia ossificans progressiva1R21TR005159-01A1 | Jeremic, Jelena Gvozdenovic | NOSTOPHARMA, LLC, MD | First-year cost $407,792 | Study section ZTR1 |
| FY2024 | Proof-of-concept for the use of enzyme replacement therapy as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome1R21TR005157-01 · under RFA-TR-23-016 | Saba, Julie D | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, CA | First-year cost $463,150 | Study section ZTR1 |
| FY2024 | Effective treatment of cystinuria with a novel engineered cyst(e)ine-degrading human enzyme therapy1R21TR005156-01 · under RFA-TR-23-016 | Georgiou, George Georgiou | UNIVERSITY OF TEXAS AT AUSTIN, TX | First-year cost $437,761 | Study section ZTR1 |
| FY2024 | Triacetin Treatment for Propionic Acidemia by Rebalancing the Acetyl-CoA/Propionyl-CoA Metabolism1R21TR005163-01 · under RFA-TR-23-016 | Chen, Xiaoxin LukeZhang, Guofang | DUKE UNIVERSITY, NC | First-year cost $184,617 | Study section ZTR1 |
| FY2024 | Durability of a gene editing therapy that restores dystrophin in a humanized mouse model of Duchenne muscular dystrophy1R21TR005162-01 · under RFA-TR-23-016 | Young, Courtney S | MYOGENE BIO, LLC, CA | First-year cost $110,000 | Study section ZTR1 |
Newest fiscal year first, then first-year cost.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-17-0.3.6. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.